
Pune: At least 25 COVID-19 patients, who are in a semi-critical condition at Pune's government-run Sassoon General Hospital, will be administered tocilizumab, a drug which has proven effective in treating the infection.
The new drug, an injection, which costs around Rs 20,000, will be given to 25 patients in the first phase and depending on the results, the Pune Municipal Corporation will decide on its further use, municipal commissioner Shekhar Gaikwad said.
Also read: South Kashmir’s Pulwama saw one policeman killed and another injured in an attack on security forces
A special task force of specialist doctors set up under the chairmanship of Dr DB Kadam recommended tocilizumab for COVID-19 patients in case their condition worsens, he said.
"After the ethical team gave approval for the use of tocilizumab, we started procuring it for 25 patients in the first phase," Gaikwad said.
The civic body had received protocols for using the drug.
Also read: Karnataka Institute of Cricket academy has reopened with new protocol
"Tocilizumab was administered to an anganwadi worker, admitted to Bharti Hospital in a critical condition, who made a remarkable recovery," he said.
Civic hospitals in Mumbai were also using the drug to treat COVID-19 patients and it has given good results, he said.
The task force has recommended the use of the drug in patients below 50 years of age, those with evidence of cytokine storm, requiring oxygen and having persistent fever.
Stay updated with the Breaking News Today and Latest News from across India and around the world. Get real-time updates, in-depth analysis, and comprehensive coverage of India News, World News, Indian Defence News, Kerala News, and Karnataka News. From politics to current affairs, follow every major story as it unfolds. Get real-time updates from IMD on major cities weather forecasts, including Rain alerts, Cyclone warnings, and temperature trends. Download the Asianet News Official App from the Android Play Store and iPhone App Store for accurate and timely news updates anytime, anywhere.